AAAAAA

   
Results: 1-12 |
Results: 12
Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade (TM) in patients with rheumatoid arthritis
Authors: Hemmings, FJ Farhan, M Rowland, J Banken, L Jain, R
Citation: Fj. Hemmings et al., Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade (TM) in patients with rheumatoid arthritis, RHEUMATOLOG, 40(5), 2001, pp. 537-543
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
Authors: Schuller, J Cassidy, J Dumont, E Roos, B Durston, S Banken, L Utoh, M Mori, K Weidekamm, E Reigner, B
Citation: J. Schuller et al., Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients, CANC CHEMOT, 45(4), 2000, pp. 291-297
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies
Authors: Jorga, K Fotteler, B Banken, L Snell, P Steimer, JL
Citation: K. Jorga et al., Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies, BR J CL PH, 49(1), 2000, pp. 39-48
Lack of interaction between tolcapone and tolbutamide in healthy volunteers
Authors: Jorga, KM Fotteler, B Gasser, R Banken, L Birnboeck, H
Citation: Km. Jorga et al., Lack of interaction between tolcapone and tolbutamide in healthy volunteers, J CLIN PHAR, 40(5), 2000, pp. 544-551
Valganciclovir results in improved oral absorption of ganciclovir in livertransplant recipients
Authors: Pescovitz, MD Rabkin, J Merion, RM Paya, CV Pirsch, J Freeman, RB O'Grady, J Robinson, C To, Z Wren, K Banken, L Buhles, W Brown, F
Citation: Md. Pescovitz et al., Valganciclovir results in improved oral absorption of ganciclovir in livertransplant recipients, ANTIM AG CH, 44(10), 2000, pp. 2811-2815
Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone
Authors: Jorga, K Banken, L Fotteler, B Snell, P Steimer, JL
Citation: K. Jorga et al., Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone, CLIN PHARM, 67(6), 2000, pp. 610-620
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
Authors: Twelves, C Glynne-Jones, R Cassidy, J Schuller, J Goggin, T Roos, B Banken, L Utoh, M Weidekamm, E Reigner, B
Citation: C. Twelves et al., Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites, CLIN CANC R, 5(7), 1999, pp. 1696-1702
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
Authors: Cassidy, J Twelves, C Cameron, D Steward, W O'Byrne, K Jodrell, D Banken, L Goggin, T Jones, D Roos, B Bush, E Weidekamm, E Reigner, B
Citation: J. Cassidy et al., Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients, CANC CHEMOT, 44(6), 1999, pp. 453-460
Influence of the antacid Maalox on the pharmacokinetics of capecitabine incancer patients
Authors: Reigner, B Clive, S Cassidy, J Jodrell, D Schulz, R Goggin, T Banken, L Roos, B Utoh, M Mulligan, T Weidekamm, E
Citation: B. Reigner et al., Influence of the antacid Maalox on the pharmacokinetics of capecitabine incancer patients, CANC CHEMOT, 43(4), 1999, pp. 309-315
Pharmacokinetics of valganciclovir and ganciclovir following multiple oraldosages of valganciclovir in HIV- and CMV-seropositive volunteers
Authors: Brown, F Banken, L Saywell, K Arum, I
Citation: F. Brown et al., Pharmacokinetics of valganciclovir and ganciclovir following multiple oraldosages of valganciclovir in HIV- and CMV-seropositive volunteers, CLIN PHARMA, 37(2), 1999, pp. 167-176
The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects
Authors: Weber, C Banken, L Birnboeck, H Nave, S Schulz, R
Citation: C. Weber et al., The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects, BR J CL PH, 47(6), 1999, pp. 701-706
Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin
Authors: Weber, C Banken, L Birnboeck, H Schulz, R
Citation: C. Weber et al., Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin, J CLIN PHAR, 39(8), 1999, pp. 847-854
Risultati: 1-12 |